Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers
Ignacio Blanco(Hospital Universitari Germans Trias i Pujol), Miguel de la Hoya, Teresa Ramón y Cajal(Hospital de Sant Pau), Jan Lubiński(Tumour Institute of Tuscany), Thomas van Overeem Hansen(University of Copenhagen), Kathleen Claes(Statistics Belgium), Pablo Librado(Universitat Pompeu Fabra), Ana Osório(Spanish National Cancer Research Centre), Daniel Barrowdale(University of Cambridge), Robert L. Nussbaum(National Institutes of Health), Amanda E. Toland(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Alejandro Sánchez‐Gracia(Departament de Salut), Irene L. Andrulis(University of Toronto), Javier Benı́tez(Spanish National Cancer Research Centre), Christine Walsh(Cedars-Sinai Medical Center), Anna Jakubowska(Pomeranian Medical University), Daniel Cuadras(Sant Joan de Déu Research Foundation), Heli Nevanlinna(University of Helsinki), Núria Bonifaci(Bellvitge University Hospital), Joan Brunet(Institut Català d'Ornitologia), Eva Tornero(Institut d'Investigació Biomédica de Bellvitge), Susan M. Domchek(University City Science Center), Francesca Mateo(Institut d'Investigació Biomédica de Bellvitge), Rósa B. Barkardóttir(University of Iceland), Katherine L. Nathanson(Translational Therapeutics (United States)), Gorka Ruíz de Garibay(Bellvitge University Hospital), Anne‐Marie Gerdes(Copenhagen University Hospital), Lídia Feliubadaló(University of Cologne), Antonio Berenguer(Institut Català d'Ornitologia), Beth Y. Karlan(University of California, Los Angeles), Xianshu Wang(Kunming University of Science and Technology), Abul Bashar Mir Md. Khademul Islam(University of Dhaka), V. Shane Pankratz(University of New Mexico), Mark H. Greene(Cancer Institute (WIA)), Julio Rozas(Departament de Salut), Banu Arun(The University of Texas MD Anderson Cancer Center), Katarzyna Jaworska-Bieniek(Pomeranian Medical University), Katarzyna Durda(Pomeranian Medical University), Kristiina Aittomäki(University of Helsinki), Lesley McGuffog(University of Cambridge), Lars Jønson(Copenhagen University Hospital), Jenny Lester(Cedars-Sinai Medical Center), Tom Van Maerken(Ghent University Hospital), Timothy R. Rebbeck(University of Pennsylvania), Bent Ejlertsen(Copenhagen University Hospital), Anna Petit(Bellvitge University Hospital), Orland Dı́ez(Vall d'Hebron Hospital Universitari), Isabel Català(Bellvitge University Hospital), Karoline Kuchenbaecker(University of Cambridge)
Cited by 39
Related Papers
Analysis of shared heritability in common disorders of the brain
|Science|2018|2k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k